アミノグリコシド市場：製品、投与経路、用途別-2025-2030年の世界予測

アミノグリコシド市場は、2023年に19億3,000万米ドルと評価され、2024年には20億2,000万米ドルに達すると予測され、CAGR 4.76％で成長し、2030年には26億7,000万米ドルになると予測されています。

アミノグリコシドは、主にグラム陰性菌による重症の細菌感染症の治療に使用される抗生物質の一種です。医療分野におけるその重要性は、敗血症や結核のような生命を脅かす感染症、特に他の抗生物質が効かない場合の治療に有効であることに起因します。アミノグリコシドの用途は、家畜のヘルスケア、食の安全の確保、疾病発生の予防において重要な役割を果たす、ヒトおよび獣医学に及びます。最終用途の範囲は、病院、診療所、研究機関、医薬品製造にまで及んでいます。アミノグリコシド市場は、抗生物質耐性の増加などの要因に影響され、効果的な治療の必要性が強調され、市場の需要を牽引しています。さらに、新興国における細菌感染症の増加も大きな成長の可能性をもたらしています。しかし、市場は厳しい規制の枠組みや、腎毒性や耳毒性など過剰使用に伴う毒性の可能性といった課題に直面しています。潜在的な可能性を探ると、副作用を軽減し有効性を高めたアミノグリコシド誘導体の開発には、かなりの技術革新の余地があります。耐性発現を抑える併用療法に焦点を当てた研究開発への投資は、市場成長をさらに促進する可能性があります。さらに、市場関係者はバイオテクノロジー企業との共同事業を模索し、アミノグリコシドの使用精度を高めるドラッグデリバリーシステムを開発すべきです。主な発展には、開発コストの高さや承認プロセスの長さなどがあり、新規参入を阻む要因となっています。しかし、抗生物質耐性研究に対する政府の優遇措置や資金援助により、経済的負担が軽減される可能性があります。個別化医療の動向は、抗生物質を個々の患者のニーズに合わせて調整することで、治療成果を最適化できる可能性があることから、市場拡大の道を示しています。市場の競争は研究主導型であるため、イノベーションと戦略的提携を優先する企業にはチャンスとなります。

市場力学：急速に進化するアミノグリコシド市場の主要市場インサイトを公開

アミノグリコシド市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • グラム陰性菌感染症に対する効果的な治療に対するニーズの高まり
  • 動物の感染症を治療するための動物用医薬品の利用
• 市場抑制要因
  • アミノグリコシドの開発と製造における複雑さ
• 市場機会
  • アミノグリコシドのドラッグデリバリーシステムの進歩
  • アミノグリコシド耐性メカニズムの研究開発
• 市場の課題
  • アミノグリコシドによる副作用と毒性

ポーターのファイブフォース：アミノグリコシド市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：アミノグリコシド市場における外部からの影響の把握

外部マクロ環境要因は、アミノグリコシド市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析アミノグリコシド市場における競合情勢の把握

アミノグリコシド市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスアミノグリコシド市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、アミノグリコシド市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨アミノグリコシド市場における成功への道筋を描く

アミノグリコシド市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • グラム陰性細菌感染症の効果的な治療法の必要性が高まっている
    • 動物の感染症治療における獣医学の利用
  • 抑制要因
    • アミノグリコシドの開発と製造における複雑さ
  • 機会
    • アミノグリコシドのドラッグデリバリーシステムの進歩
    • アミノグリコシド耐性機構の研究開発
  • 課題
    • アミノグリコシドによる副作用と毒性
• 市場セグメンテーション分析
  • 製品：血液、腹部、肺、皮膚、軟部組織の感染症の治療に広く利用されているゲンタマイシン
  • 応用：呼吸器疾患全般にわたるアミノグリコシドの活用
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 アミノグリコシド市場：製品別

• アミカシン
• ゲンタマイシン
• カナマイシン
• ネオマイシン
• パロモマイシン
• ストレプトマイシン
• トブラマイシン

第7章 アミノグリコシド市場：投与経路別

• 注射剤
• オーラル
• 話題

第8章 アミノグリコシド市場：用途別

• 呼吸器疾患
• 皮膚感染症
• 尿路感染症と骨盤疾患
• 獣医学

第9章 南北アメリカのアミノグリコシド市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のアミノグリコシド市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのアミノグリコシド市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • シプラ・リミテッド、インドで進行性尿路感染症治療薬プラゾマイシンを発表
  • 安全性向上のためのアミノグリコシド系抗生物質の革新：難聴リスクの軽減
  • BDR Pharmaceuticals、希少小児および成人白血病治療における新たなアプローチ、ニロチニブを発売
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• AstraZeneca plc
• Bristol Myers Squibb Company
• Cipla Limited
• GlaxoSmithKline plc
• Hangzhou Uniwise International Co., Ltd.
• HuvePharma
• Insmed Incorporated
• Jiangxi Bolai Pharmacy Co., Ltd.
• Kremoint Pharma Pvt. Ltd
• Medico Remedies Pvt. Ltd.
• Medson Pharmaceuticals
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd
• Vega Pharma Ltd.
• Zoetis Inc.

LIST OF FIGURES

• FIGURE 1. AMINOGLYCOSIDES MARKET RESEARCH PROCESS
• FIGURE 2. AMINOGLYCOSIDES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL AMINOGLYCOSIDES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS AMINOGLYCOSIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS AMINOGLYCOSIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES AMINOGLYCOSIDES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES AMINOGLYCOSIDES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC AMINOGLYCOSIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC AMINOGLYCOSIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AMINOGLYCOSIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AMINOGLYCOSIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. AMINOGLYCOSIDES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. AMINOGLYCOSIDES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. AMINOGLYCOSIDES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL AMINOGLYCOSIDES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. AMINOGLYCOSIDES MARKET DYNAMICS
• TABLE 7. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY AMIKACIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY GENTAMICIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY KANAMYCIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY NEOMYCIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY PAROMOMYCIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY STREPTOMYCIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY TOBRAMYCIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY SKIN INFECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY UTI & PELVIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY VETERINARY MEDICINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS AMINOGLYCOSIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. CANADA AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 35. CANADA AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 36. CANADA AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES AMINOGLYCOSIDES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC AMINOGLYCOSIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 48. AUSTRALIA AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 49. AUSTRALIA AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 50. AUSTRALIA AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. CHINA AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 52. CHINA AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 53. CHINA AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. INDIA AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 55. INDIA AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 56. INDIA AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. INDONESIA AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. INDONESIA AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 59. INDONESIA AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. JAPAN AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 61. JAPAN AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. JAPAN AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. MALAYSIA AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 64. MALAYSIA AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 65. MALAYSIA AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. PHILIPPINES AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 67. PHILIPPINES AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. PHILIPPINES AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. SINGAPORE AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 70. SINGAPORE AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 71. SINGAPORE AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. SOUTH KOREA AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 73. SOUTH KOREA AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. SOUTH KOREA AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. TAIWAN AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 76. TAIWAN AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 77. TAIWAN AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. THAILAND AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. THAILAND AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 80. THAILAND AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. VIETNAM AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 82. VIETNAM AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 83. VIETNAM AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. EUROPE, MIDDLE EAST & AFRICA AMINOGLYCOSIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 88. DENMARK AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 89. DENMARK AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 90. DENMARK AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. EGYPT AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 92. EGYPT AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 93. EGYPT AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. FINLAND AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. FINLAND AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 96. FINLAND AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. FRANCE AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 98. FRANCE AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 99. FRANCE AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. GERMANY AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 101. GERMANY AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 102. GERMANY AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. ISRAEL AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 104. ISRAEL AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 105. ISRAEL AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. ITALY AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 107. ITALY AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 108. ITALY AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. NETHERLANDS AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 110. NETHERLANDS AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 111. NETHERLANDS AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 112. NIGERIA AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 113. NIGERIA AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 114. NIGERIA AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. NORWAY AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 116. NORWAY AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 117. NORWAY AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. POLAND AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 119. POLAND AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 120. POLAND AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. QATAR AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 122. QATAR AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. QATAR AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. RUSSIA AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 125. RUSSIA AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 126. RUSSIA AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. SAUDI ARABIA AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 128. SAUDI ARABIA AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 129. SAUDI ARABIA AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH AFRICA AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH AFRICA AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH AFRICA AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. SPAIN AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 134. SPAIN AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 135. SPAIN AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 136. SWEDEN AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 137. SWEDEN AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 138. SWEDEN AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. SWITZERLAND AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 140. SWITZERLAND AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 141. SWITZERLAND AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 142. TURKEY AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 143. TURKEY AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. TURKEY AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. UNITED ARAB EMIRATES AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 146. UNITED ARAB EMIRATES AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 147. UNITED ARAB EMIRATES AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 148. UNITED KINGDOM AMINOGLYCOSIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 149. UNITED KINGDOM AMINOGLYCOSIDES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 150. UNITED KINGDOM AMINOGLYCOSIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 151. AMINOGLYCOSIDES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 152. AMINOGLYCOSIDES MARKET, FPNV POSITIONING MATRIX, 2023

The Aminoglycosides Market was valued at USD 1.93 billion in 2023, expected to reach USD 2.02 billion in 2024, and is projected to grow at a CAGR of 4.76%, to USD 2.67 billion by 2030.

Aminoglycosides are a class of antibiotics used primarily to treat severe bacterial infections, particularly those caused by gram-negative bacteria. Their importance in the medical field stems from their effectiveness in treating life-threatening infections like sepsis and tuberculosis, especially when other antibiotics fail. The application of aminoglycosides spans human and veterinary medicine, where they play a crucial role in livestock healthcare, ensuring food safety, and the prevention of disease outbreaks. The end-use scope extends to hospitals, clinics, research institutions, and pharmaceutical manufacturing. The market for aminoglycosides is influenced by factors such as rising antibiotic resistance, which underscores the necessity for effective treatments and drives market demand. Additionally, the growing incidences of bacterial infections in emerging economies provide significant growth potential. However, the market faces challenges from stringent regulatory frameworks and the potential for toxicity associated with overuse, such as nephrotoxicity and ototoxicity. Exploring potential opportunities, there is considerable room for innovation in developing aminoglycoside derivatives with reduced side effects and enhanced efficacy. Investment in research focused on combination therapies that reduce resistance development can further propel market growth. Moreover, market players should explore joint ventures with biotechnological firms to advance drug delivery systems that enhance the precision of aminoglycoside usage. Key limitations include the high cost of development and the lengthy approval process, which can deter new entrants. However, government incentives and funding for antibiotic resistance research may alleviate some financial burdens. Trends toward personalized medicine present an avenue for market expansion, as tailoring antibiotics to individual patient needs could optimize therapeutic outcomes. The nature of the aminoglycosides market is competitive and research-driven, presenting opportunities for enterprises that prioritize innovation and strategic collaborations.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Aminoglycosides Market

The Aminoglycosides Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rise in need for effective treatments for gram-negative bacterial infections
  • Utilization veterinary medicine to treat infections in animals
• Market Restraints
  • Complexities in development and manufacturing of aminoglycosides
• Market Opportunities
  • Advancements in drug delivery systems for aminoglycosides
  • Research and development into aminoglycoside resistance mechanisms
• Market Challenges
  • Side effects and toxicity caused due to aminoglycosides

Porter's Five Forces: A Strategic Tool for Navigating the Aminoglycosides Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Aminoglycosides Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Aminoglycosides Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Aminoglycosides Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Aminoglycosides Market

A detailed market share analysis in the Aminoglycosides Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Aminoglycosides Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Aminoglycosides Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Aminoglycosides Market

A strategic analysis of the Aminoglycosides Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Aminoglycosides Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AstraZeneca plc, Bristol Myers Squibb Company, Cipla Limited, GlaxoSmithKline plc, Hangzhou Uniwise International Co., Ltd., HuvePharma, Insmed Incorporated, Jiangxi Bolai Pharmacy Co., Ltd., Kremoint Pharma Pvt. Ltd, Medico Remedies Pvt. Ltd., Medson Pharmaceuticals, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd, Vega Pharma Ltd., and Zoetis Inc..

Market Segmentation & Coverage

This research report categorizes the Aminoglycosides Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Amikacin, Gentamicin, Kanamycin, Neomycin, Paromomycin, Streptomycin, and Tobramycin.
• Based on Route of Administration, market is studied across Injectables, Oral, and Topical.
• Based on Application, market is studied across Respiratory Diseases, Skin Infection, UTI & Pelvic Diseases, and Veterinary Medicine.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rise in need for effective treatments for gram-negative bacterial infections
    • 5.1.1.2. Utilization veterinary medicine to treat infections in animals
  • 5.1.2. Restraints
    • 5.1.2.1. Complexities in development and manufacturing of aminoglycosides
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in drug delivery systems for aminoglycosides
    • 5.1.3.2. Research and development into aminoglycoside resistance mechanisms
  • 5.1.4. Challenges
    • 5.1.4.1. Side effects and toxicity caused due to aminoglycosides
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Wide utilization of gentamicin to treat infections in the blood, abdomen, lungs, skin, and soft tissues
  • 5.2.2. Application: Employment of aminoglycosides across respiratory diseases
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Aminoglycosides Market, by Product

• 6.1. Introduction
• 6.2. Amikacin
• 6.3. Gentamicin
• 6.4. Kanamycin
• 6.5. Neomycin
• 6.6. Paromomycin
• 6.7. Streptomycin
• 6.8. Tobramycin

7. Aminoglycosides Market, by Route of Administration

• 7.1. Introduction
• 7.2. Injectables
• 7.3. Oral
• 7.4. Topical

8. Aminoglycosides Market, by Application

• 8.1. Introduction
• 8.2. Respiratory Diseases
• 8.3. Skin Infection
• 8.4. UTI & Pelvic Diseases
• 8.5. Veterinary Medicine

9. Americas Aminoglycosides Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Aminoglycosides Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Aminoglycosides Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Cipla Limited Unveils Plazomicin for Advanced Urinary Tract Infection Management in India
  • 12.3.2. Innovating Aminoglycoside Antibiotics for Enhanced Safety: Mitigating Hearing Loss Risks
  • 12.3.3. BDR Pharmaceuticals Launches Nilotinib: A Novel Approach in the Treatment of Rare Childhood and Adult Leukemia
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. AstraZeneca plc
• 3. Bristol Myers Squibb Company
• 4. Cipla Limited
• 5. GlaxoSmithKline plc
• 6. Hangzhou Uniwise International Co., Ltd.
• 7. HuvePharma
• 8. Insmed Incorporated
• 9. Jiangxi Bolai Pharmacy Co., Ltd.
• 10. Kremoint Pharma Pvt. Ltd
• 11. Medico Remedies Pvt. Ltd.
• 12. Medson Pharmaceuticals
• 13. Novartis AG
• 14. Pfizer Inc.
• 15. Teva Pharmaceutical Industries Ltd
• 16. Vega Pharma Ltd.
• 17. Zoetis Inc.